CAM
KROS icon

Cormorant Asset Management’s Keros Therapeutics KROS Stock Holding History

Cormorant Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$4.8M – 80
2022
Q4 		$4.8M Hold
100,000
– – 0.32% 58
2022
Q3 		$3.76M Hold
100,000
– – 0.26% 54
2022
Q2 		$2.76M Hold
100,000
– – 0.21% 60
2022
Q1 		$5.44M Sell
100,000
-50,000
-33% -$2.57M 0.42% 49
2021
Q4 		$8.78M Buy
+150,000
New +$7.48M 0.52% 46

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Cormorant Asset Management's KROS Position: Q1 2023 in Review

Cormorant Asset Management sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 100,000 shares — an estimated $4.8M sold.

Cormorant Asset Management first reported a position in KROS in Q4 2021 and held it in 5 quarters. The position peaked at $8.78M in Q4 2021. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

  • Cormorant Asset Management reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 100,000 Keros Therapeutics shares in Q1 2023, an estimated $4.8M.
  • Cormorant Asset Management first reported a position in Keros Therapeutics in Q4 2021 and held it in 5 quarters.
  • Cormorant Asset Management's Keros Therapeutics position peaked at $8.78M in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.